Additionally, we characterized two independent potential resistance mechanisms to mSWI/SNF PROTAC degraders in prostate cancer models: one driven by mutations in the bromodomain of SMARCA4 and the other driven by ABCB1 elevation. This evidence concerns the gene SMARCA4 and prostate carcinoma.